Harper, M.D., executive vice president of Development and Study at Amgen. Etelcalcetide has the potential to fill this unmet need, and we look forward to working with regulatory authorities in hopes of providing a new treatment option that may help improve the complex management of the disease. The MAA submission for etelcalcetide contains data from three Stage 3 studies, which met their major endpoints, including two pooled placebo-controlled trials in a lot more than 1,000 patients and a head-to-head study evaluating etelcalcetide compared with cinacalcet.. Amgen announces MAA submission to EMA for novel calcimimetic agent etelcalcetide Amgen today announced the submission of a Advertising Authorization Program to the European Medications Agency via the centralized process of etelcalcetide for the treatment of secondary hyperparathyroidism in adult individuals with chronic kidney disease on hemodialysis therapy.The scholarly research yielded startling results, suggesting that genetics perform a much larger part in disc degeneration than previously believed. The Twin Spine Research is definately not over: having found proof that genetics may play an overlooked part in disk degeneration, the group of UNITED STATES and European is currently working to determine the precise genes and biological mechanisms influencing disk degeneration and back discomfort problems; focusing on how degeneration progresses as time passes; and differentiating regular, inconsequential adjustments from degenerative adjustments that result in pain..